Summary
Requires the government to list essential medicines, check their supply chains for risks, and create a system to watch over them to prevent shortages.
What problem does this solve?
The U.S. does not have a clear view of where its essential medicines come from, creating risks of shortages and dependence on other countries. This bill creates a system to map the entire drug supply chain to find and fix these weak spots before they become a problem.
Who does this affect?
- Pharmaceutical manufacturers
- Federal health and defense agencies
- Patients with chronic conditions
What does this bill do?
Creates an essential medicines list
Requires the government to make and regularly update a list of medicines that are most important for health care, responding to national threats, and for military readiness.
Assesses supply chain risks
Mandates a full review of the supply chains for essential medicines to find weak spots, such as heavy reliance on foreign suppliers or cybersecurity threats.
Maps the pharmaceutical supply chain
Directs the government to use data and technology to create a map of the entire supply chain for essential drugs, from raw materials to the final product.
Requires reports on drugs from China
Forces the Department of Defense to report to Congress twice a year on all drugs it buys that were made in or used ingredients from the People's Republic of China.
Protects confidential company information
Allows federal agencies to share supply chain information with each other without breaking the law, but clarifies this information should still be protected as a trade secret.
What is the real world impact?
•
Prevents future drug shortages
Creates a system to identify essential medicines and monitor their supply chains. This helps the government spot potential shortages early and take action to prevent them, ensuring patients can get the medicines they need.
•
Reduces reliance on foreign countries for medicine
Identifies which critical drugs and ingredients are sourced from other countries, especially China. This information can be used to encourage more drug manufacturing in the U.S., making the country less vulnerable to international conflicts or disasters.
•
Increases government oversight of private industry
Requires drug companies to share detailed information about their manufacturing and supply chains with the government. Some may see this as necessary for national security, while others might worry about government overreach and the security of private business data.
When does this start?
This bill sets several deadlines for reports and actions that begin shortly after it becomes law.
Initial essential medicines list
The first version of the essential medicines list must be completed within 180 days of the bill becoming law.
First risk assessment report
The first report on supply chain risks must be sent to Congress within 180 days.
First report on drugs from China
The Department of Defense must submit its first report on drugs sourced from China within 180 days.
First supply chain mapping report
The first report on the progress of mapping drug supply chains is due to Congress within 18 months.
Ongoing updates and reports
The essential medicines list must be updated at least every two years, while risk and mapping reports are due every year.